Table 1.
Patient and disease characteristics by treatment group.
| Characteristics | SRS | Surgery + SRS | WBRT + SRS | p value |
|---|---|---|---|---|
| Number of patients | 36 | 24 | 6 | |
| Age (years) | ||||
| Median age | 60.5 | 58 | 59 | 0.5622 |
| Mean age | 58.6 | 58.1 | 62.8 | |
| Range | 31–79 | 40–85 | 54–81 | |
| Sex | ||||
| Male | 37 (75%) | 19 (79.2%) | 1 (16.7%) | 0.909 |
| Female | 9 (25%) | 5 (20.8%) | 5 (83.3%) | |
| Systemic disease status at the time of SRS | ||||
| Controlled | 3 (8.3%) | 6 (25%) | 1 (16.7%) | 0.169 |
| Uncontrolled | 33 (91.7%) | 18 (75%) | 5 (83.3%) | |
| Intracranial disease status at the time of SRS | ||||
| Controlled | 0 (0%) | 12 (50%) | 1 (16.7%) | <0.0001 |
| Uncontrolled | 36 (100%) | 12 (50%) | 5 (83.3%) | |
| RPA | ||||
| I | 0 (0%) | 3 (12.5%) | 0 (0%) | 0.1379 |
| II | 34 (94.4%) | 20 (83.3%) | 5 (83.3%) | |
| III | 2 (5.6%) | 1 (4.2%) | 1 (16.7%) | |
| KPS | ||||
| ≥70 | 34 (94.4%) | 23 (95.8%) | 5 (83.3%) | 0.521 |
| <70 | 2 (5.6%) | 1 (4.2%) | 1 (16.7%) | |
| SIR | ||||
| ≥6 | 20 (55.6%) | 11 (45.8%) | 0 (0%) | 0.041 |
| <6 | 16 (44.4%) | 13 (54.2%) | 6 (100%) | |
| Ds-GPA | ||||
| 4 | 18 (50%) | 9 (37.5%) | 0 (0%) | 0.0073 |
| 3 | 8 (22.2%) | 9 (37.5%) | 1 (16.7%) | |
| 2 | 8 (22.2%) | 4 (16.7%) | 2 (33.3%) | |
| 1 | 2 (5.6%) | 2 (8.3%) | 2 (33.3%) | |
| 0 | 0 (0%) | 0 (0%) | 1 (16.7%) | |
| BSBM | ||||
| 3 | 0 (0%) | 2 (8.3%) | 0 (0%) | 0.6526 |
| 2 | 3 (8.3%) | 4 (16.7%) | 1 (16.7%) | |
| 1 | 28 (77.8%) | 13 (64.2%) | 3 (50%) | |
| 0 | 5 (13.9%) | 5 (20.8%) | 2 (33.3%) | |
| Number of brain metastases | ||||
| ≤3 | 33 (91.7%) | 23 (95.8%) | 2 (33.3%) | 0.002 |
| >3 | 3 (8.7%) | 1 (4.2%) | 4 (66.7%) | |
| Initial tumor volume (cm3) | ||||
| Median initial tumor volume | 1.151 | 11.746 | 1.945 | 0.0001 |
| Mean initial tumor volume | 3.3770 | 11.411 | 9.295 | |
| Range | 0.241–27.73 | 2.178–26.51 | 0.192–33.57 |
Fisher and Kruskal-Wallis test.